Eli Lilly has entered into an agreement to acquire all shares of CoLucid Pharmaceuticals for a purchase price of US$960 M to gain a late stage asset, lasmiditan, which is in development for the treatment of migraine. Lilly had originally developed lasmiditan and out-licensed it to Co-Lucid back in 2006 when pain was not Lilly’s area of focus but the now the re-acquisition strengthens its pain portfolio which also includes a calcitonin gene related peptide monoclonal antibody, galcanezumab and another antibody, tanezumab, both in development for various pain indications.